Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Class A Common Stock, $0.00001 par value per share
-
Shares outstanding
-
4,564,846
-
Total 13F shares
-
324,132,553
-
Share change
-
+13,997,527
-
Total reported value
-
$1,581,669,682
-
Put/Call ratio
-
63%
-
Price per share
-
$4.88
-
Number of holders
-
320
-
Value change
-
+$66,831,039
-
Number of buys
-
174
-
Number of sells
-
127
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) as of Q3 2025
As of 30 Sep 2025,
RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) was held by
320 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
324,132,553 shares.
The largest 10 holders included
VANGUARD GROUP INC, ARK Investment Management LLC, BlackRock, Inc., BAILLIE GIFFORD & CO, STATE STREET CORP, SOFTBANK GROUP CORP., KINNEVIK AB (PUBL), Mubadala Investment Co PJSC, MIC Capital Management UK LLP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
320
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.